| |
Tuesday, April 16, 2024 | 1pm ET / 10am PT As healthcare marketers increase programmatic investments, cookies are on the verge of going away. We want you to be prepared for the post-cookie world with a unique approach that focuses on customer-centricity and first-party data. Join usto learn how to optimize, evaluate, and access high-quality data providers for omnichannel success. Register now. 
|
|
| By Max Bayer Sanofi is laying off staff around the globe following a 'full pipeline reprioritization,' according to an email from R&D chief Houman Ashrafian to staff. The communication, obtained by Fierce Biotech, refer to a large-scale restructuring to afford late-stage drug development. |
|
|
|
By Fraiser Kansteiner Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in its development organizational unit. |
By Fraiser Kansteiner Facing lackluster Cyltezo sales, Boehringer Ingelheim will prune its ranks in the U.S. and adopt a different way of marketing its Humira biosimilar. |
By James Waldron Merck & Co. led the antibody-drug conjugate shopping spree last year with its multi-billion dollar deal with Daiichi Sankyo, but the U.S. pharma clearly wants to further fine-tune its ADC pipeline. |
|
Wednesday, April 17, 2024 | 12pm ET / 9am PT Register now to create effective pharma marketing campaigns by targeting both HCPs and consumers. Discover strategies for linking patient-physician interactions and utilizing social determinants of health data. Gain insights on identifying relevant HCPs, creating consumer audiences, and tailoring messages for maximum impact. 
|
|
By Angus Liu At the inaugural AACR Oncology Industry Partnering Event, the FDA's oncology chief Richard Pazdur, M.D., addressed some key topics at his department, including accelerated approval and confirmatory trial requirement, advisory committee meeting, some new regulatory initiatives and even his succession plan. |
By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Fraiser Kansteiner After Novo Holdings pitched a $16.5 billion buyout of Catalent in February, the companies have given the FTC extra time to review the deal. |
By Helen Floersh The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. Now, a new startup founded by two genetic medicine luminaries and run by former executives from bluebird bio is officially emerging from stealth mode to reveal its solutions to the industry. |
By Conor Hale J&J MedTech sees Shockwave’s devices for cracking open calcified arteries as the ticket to its 13th billion-dollar platform. |
By Ben Adams It’s as you were at the top of the pharma drug ad spending list in March as AbbVie’s immunology blockbusters Rinvoq and Skyrizi stay first and second, respectively. |
By Joseph Keenan India’s Jubilant Generics and Contract Pharmaceuticals Limited Canada were each hit with Form 483s by the FDA following inspections that uncovered questionable manufacturing practices. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we are exploring a topic that hits close to home for many: the struggles faced by LGBTQ+ patients, particularly trans men, when seeking healthcare services. |
|
|---|
|
|
|
Tuesday, April 23, 2024 | 1pm ET / 10am PT Join us as we dive into the pivotal challenges facing clinical trial enrollment today. Learn about innovative strategies and solutions for quickly identifying the right patients for specific therapies, the optimal time in their health journey to engage, and how to successfully activate them for trial enrollment. Register now. 
|
|
Executive Summary Learn about the current state of biopharma logistics with insights from 150 manufacturers in this exclusive market survey report. Download the report to learn about how regulatory factors and emerging therapies are having an effect on logistics. Sponsored by: Cardinal Health 3PL Services |
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper Clinical trials demand accurate lab data. Central labs uphold standards by ensuring consistency in methodologies, equipment, and reporting. Robust and integrated analytical platforms can support this via real-time access to study and lab data with transparent reporting capabilities, as well as to facilitate critical clinical decision-making and solve drug developers' challenges. Learn more about Preclarus®️ Lab Solutions by PPD®️ from expert Chris Clendening in this paper. PPD®️ Laboratory Services |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
Whitepaper Selecting a 3PL with a proven track record of delivering high-quality services is critical to a successful pharma supply chain. Here's how. BioCare |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
